Bafna Pharma

Chennai, India Founded: 1981 • Age: 45 yrs Listed
Provider of formulation services for pharmaceutical industry

About Bafna Pharma

Bafna Pharma is a publicly listed company based in Chennai (India) founded in 1981. Provider of formulation services for pharmaceutical industry. The company has 325 employees. Its Indian entity Bafna Pharmaceuticals Limited reported revenue of β‚Ή155 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.

Company details

Bafna Pharma was established in 1981 in Chennai, India, within the pharmaceutical sector. Manufacturing services focused on formulations are offered, with emphasis on exports to regulated and rest-of-world markets. Domestic operations were initiated in 2011 through the acquisition and launch of Raricap, targeting gynaec and paediatric segments. The company operates from its base in India to serve global and local needs.

  • Headquarters Chennai, India
  • Employees 325
  • Stage Public
  • Sectors
    Healthcare
  • Website bafnapharma.com
  • Social LinkedIn X
  • Legal Name Bafna Pharmaceuticals Limited
Key Metrics
  • Market Cap
    ₹1,134 Cr

    BAFNAPH · NSE

  • Share Price
    ₹469.95

    -1.99% today

  • Revenue
    ₹42.47 Cr

    FY 2019-20 · -2.7% YoY

  • EBITDA
    −₹21.33 Cr

    Margin -50.2%

  • Net Profit
    −₹2.17 Cr

    FY 2019-20 · +89.1% YoY

  • Debt / Equity
    0.70

    Interest cover -0.4x

  • Employee Count
    325

Board of directors of Bafna Pharmaceuticals Limited (Bafna Pharma)

Bafna Pharmaceuticals Limited is the primary company behind Bafna Pharma. The board of Bafna Pharmaceuticals Limited currently have 6 directors; the longest-serving is Shanmugam Hemalatha, appointed in 2020. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Shanmugam Hemalatha
DIN 02714329
Whole-time director10 Sep 20206 yrs 2 moBafna Pharmaceuticals Limited
Akila Chintalapati Raju
DIN 07590312
Director10 Sep 20206 yrs 2 moBafna Pharmaceuticals Limited
Ravichandran Chitra
DIN 07749125
Director12 Nov 20206 yrsBafna Pharmaceuticals Limited
Vinayak Dinesh Dendukuri
DIN 07601309
Whole-time director26 Jun 20233 yrs 4 moBafna Pharmaceuticals Limited
Upendar Mekala Reddy
DIN 08898174
Director26 Jun 20233 yrs 4 moBafna Pharmaceuticals Limited
Palamadai Krishnan Sundaresan
DIN 06954189
Director19 Sep 20251 yr 2 moBafna Pharmaceuticals Limited

IPO & Listings of Bafna Pharma

Bafna Pharma is a publicly listed company on the NSE with ticker symbol BAFNAPH in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date27 Feb 2020
  • Listed onNSE: BAFNAPH
  • Listed entityBafna Pharmaceuticals Limited
  • Exchange sectorHealth technology
  • ISININE878I01022
  • Share price₹443.50 (+1.99% on the day) · 2026-10-14
  • Market capitalisation₹1,046 Cr
  • Price to earnings134.7
  • EPS (diluted, trailing year)₹3.29
  • Volume (last session)2,305

Financials of Bafna Pharma

Exchange-reported figures of Bafna Pharmaceuticals Limited, the listed company behind Bafna Pharma (NSE: BAFNAPH).

Financial Highlights

FY 2019-20 Β· Consolidated
Revenue
₹42.47 Cr
-2.7% YoY
EBITDA
−₹21.33 Cr
-63.2% YoY
Profit After Tax
−₹2.17 Cr
+89.1% YoY
Net Worth
₹51.12 Cr
+168.2% YoY
Total Assets
₹54.21 Cr
-17.5% YoY
Total Debt
₹3.02 Cr
-93.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2019-20FY 2018-19FY 2017-18FY 2016-17FY 2015-16FY 2014-15FY 2013-14
Income statement
Revenue42.4743.6347.1764.9685.3297.67185
Revenue growth-2.7%-7.5%-27.4%-23.9%-12.6%-47.3%-
EBITDA(21.33)(13.07)(35.12)(5.82)0.51(20.51)22.83
EBITDA margin-50.2%-30.0%-74.5%-9.0%+0.6%-21.0%+12.3%
Profit before tax(24.44)(17.28)(14.70)(20.37)(15.33)6.052.48
Net profit(2.17)(19.88)(44.56)(19.10)(14.04)(29.86)1.39
Net profit margin-5.1%-45.6%-94.5%-29.4%-16.5%-30.6%+0.8%
EPS (β‚Ή)0.000.000.000.000.003.310.75
Balance sheet
Total assets54.2165.7196.70137139142179
Net worth51.1219.0637.9342.6757.7671.7868.86
Total debt3.0246.2346.5482.3880.4868.65108
Cash & bank8.482.712.952.662.712.772.81
Net working capital18.990.8812.1739.0972.7373.02106
Cash flow
Cash from operations(34.31)(1.79)(7.05)(0.95)0.9110.661.61
Cash from investing32.7715.3637.97(5.42)(0.36)60.13(6.71)
Cash from financing7.30(13.81)(30.63)6.31(0.61)(70.83)(13.16)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue15114615211585.1471.2242.47
Revenue growth+3.3%-4.3%+32.2%+35.5%+19.6%+67.7%-
EBITDA15.949.0311.1115.709.8010.30(22.10)
EBITDA margin+10.6%+6.2%+7.3%+13.6%+11.5%+14.5%-52.0%
Profit before tax10.974.157.3411.605.225.83(25.21)
Net profit11.106.377.2711.127.385.83(1.88)
Net profit margin+7.4%+4.4%+4.8%+9.6%+8.7%+8.2%-4.4%
EPS (β‚Ή)4.691.763.114.792.212.46(106.54)
Balance sheet
Total assets13811510797.6073.8772.1653.96
Net worth96.1584.8180.8473.4661.9756.7750.95
Total debt37.4328.2024.3922.9311.0615.293.02
Cash & bank2.023.431.407.810.171.808.48
Net working capital52.1247.0553.3355.3234.6135.3518.77
Cash flow
Cash from operations15.3722.149.484.959.73(13.61)(34.27)
Cash from investing(22.40)(21.16)(15.05)(7.49)(6.54)(5.35)32.78
Cash from financing5.621.06(0.85)10.18(4.81)12.287.27
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue47.6726.5842.2438.2935.4734.6239.0633.19
Revenue growth (YoY)+34.4%-23.2%+8.1%+15.4%-12.0%+4.0%--
Other income1.131.911.761.221.180.601.030.19
Total expenses39.0625.7038.6935.2431.1929.5637.7430.14
EBITDA8.610.883.553.054.285.061.323.05
EBITDA margin+18.1%+3.3%+8.4%+8.0%+12.1%+14.6%+3.4%+9.2%
Depreciation1.871.781.661.571.471.370.221.66
Interest1.020.941.030.860.860.910.820.64
Profit before tax6.850.072.621.843.133.381.310.94
Tax0.000.00(0.13)0.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Nov 2026
ParticularsFY 2019-20FY 2018-19FY 2017-18FY 2016-17FY 2015-16FY 2014-15FY 2013-14
Revenue42.4743.6347.1764.9685.3297.67185
Revenue growth-2.7%-7.5%-27.4%-23.9%-12.6%-47.3%-
Other income0.261.4031.331.141.9846.011.85
Total expenses63.8056.7082.2970.7884.81118162
Employee cost10.259.017.476.816.9910.7814.24
EBITDA(21.33)(13.07)(35.12)(5.82)0.51(20.51)22.83
EBITDA margin-50.2%-30.0%-74.5%-9.0%+0.6%-21.0%+12.3%
Depreciation3.273.483.974.224.865.998.99
Interest0.102.136.9411.4712.9613.4613.21
Profit before tax(24.44)(17.28)(14.70)(20.37)(15.33)6.052.48
Tax0.001.072.19(0.90)(0.18)(0.15)1.05
Net profit(2.17)(19.88)(44.56)(19.10)(14.04)(29.86)1.39
Net profit margin-5.1%-45.6%-94.5%-29.4%-16.5%-30.6%+0.8%
EPS (β‚Ή)0.000.000.000.000.003.310.75
ParticularsFY 2019-20FY 2018-19FY 2017-18FY 2016-17FY 2015-16FY 2014-15FY 2013-14
Equity & liabilities
Share capital2.3723.6623.6618.6618.6618.6618.66
Reserves & surplus(6.61)(4.60)14.2720.0139.1053.1250.20
Shareholders' funds (net worth)51.1219.0637.9342.6757.7671.7868.86
Minority interest0.08(0.21)(0.73)(0.55)0.000.930.89
Secured loans0.0044.1044.3780.1480.4868.65108
Unsecured loans3.022.132.172.240.000.000.00
Total debt3.0246.2346.5482.3880.4868.65108
Total liabilities54.2165.7196.70137139142179
Assets
Gross block74.1372.9179.7779.6579.6777.3690.61
Net block35.0137.0544.8948.6152.6154.5669.28
Capital work in progress0.210.000.000.000.000.000.00
Investments0.000.000.0016.9016.9016.900.00
Inventories11.419.2810.6716.7416.3816.1227.40
Sundry debtors6.0324.8324.2853.7867.9688.6997.51
Cash & bank balances8.482.712.952.662.712.772.81
Loans & advances10.1711.6410.834.0135.4219.5128.76
Total current assets36.0948.4648.7377.19122127156
Total current liabilities17.1047.5836.5638.1049.7454.0750.16
Net working capital18.990.8812.1739.0972.7373.02106
Total assets54.2165.7196.70137139142179
ParticularsFY 2019-20FY 2018-19FY 2017-18FY 2016-17FY 2015-16FY 2014-15FY 2013-14
Opening cash2.712.952.662.712.772.8121.07
Net cash from operating activities(34.31)(1.79)(7.05)(0.95)0.9110.661.61
Net cash from investing activities32.7715.3637.97(5.42)(0.36)60.13(6.71)
Net cash from financing activities7.30(13.81)(30.63)6.31(0.61)(70.83)(13.16)
Net change in cash5.77(0.24)0.29(0.06)(0.06)(0.04)(18.26)
Closing cash8.482.712.952.662.712.772.81
ParticularsFY 2019-20FY 2018-19FY 2017-18FY 2016-17FY 2015-16FY 2014-15FY 2013-14
Growth
Sales growth-2.7%-7.5%-27.4%-23.9%-12.6%-47.3%-
EBITDA growth-63.2%+62.8%-503.4%-1241.2%+102.5%-189.8%-
PBT growth-41.4%-17.6%+27.8%-32.9%-+144.0%-54.9%
Net income growth+89.1%+55.4%-133.3%-36.0%+53.0%-2248.2%-
Revenue CAGR (3Y)-13.2%-20.0%-21.5%-29.5%-21.4%--
EBITDA CAGR (3Y)+54.2%-+19.6%--71.7%--
Profitability & leverage
Net income margin-57.6%-42.1%-35.8%-30.0%-17.8%+6.4%+0.8%
Return on capital employed0.0%0.0%0.0%0.0%-1.7%-11.8%+9.0%
Return on net worth0.0%0.0%0.0%0.0%-23.4%-42.4%+2.1%
Debt / equity0.701.631.601.621.151.261.53
Long-term debt / equity0.340.410.050.370.360.250.35
Interest cover-0.41-12.87-17.75-114.24-297.93-50.7995.45
Efficiency & per share
Fixed asset turnover0.580.570.590.821.101.172.10
Inventory turnover4.114.373.443.925.324.537.48
Debtors turnover2.751.781.211.071.101.061.96
EPS (β‚Ή)0.000.000.000.000.003.310.75
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)(17.93)8.0616.0320.7330.9638.4736.91
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue47.6726.5842.2438.2935.4734.6239.0633.19
Revenue growth (YoY)+34.4%-23.2%+8.1%+15.4%-12.0%+4.0%--
Other income1.131.911.761.221.180.601.030.19
Total expenses39.0625.7038.6935.2431.1929.5637.7430.14
EBITDA8.610.883.553.054.285.061.323.05
EBITDA margin+18.1%+3.3%+8.4%+8.0%+12.1%+14.6%+3.4%+9.2%
Depreciation1.871.781.661.571.471.370.221.66
Interest1.020.941.030.860.860.910.820.64
Profit before tax6.850.072.621.843.133.381.310.94
Tax0.000.00(0.13)0.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue15114615211585.1471.2242.47
Revenue growth+3.3%-4.3%+32.2%+35.5%+19.6%+67.7%-
Other income4.762.743.523.271.700.750.26
Total expenses13513714199.6575.3460.9264.57
Employee cost21.9221.0319.0315.8714.6511.9810.25
EBITDA15.949.0311.1115.709.8010.30(22.10)
EBITDA margin+10.6%+6.2%+7.3%+13.6%+11.5%+14.5%-52.0%
Depreciation6.074.895.005.335.494.483.27
Interest3.662.732.292.040.790.740.10
Profit before tax10.974.157.3411.605.225.83(25.21)
Tax(0.13)0.000.000.280.000.000.00
Net profit11.106.377.2711.127.385.83(1.88)
Net profit margin+7.4%+4.4%+4.8%+9.6%+8.7%+8.2%-4.4%
EPS (β‚Ή)4.691.763.114.792.212.46(106.54)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.6623.6623.6623.6623.6623.662.37
Reserves & surplus72.4961.1557.1849.8038.3133.11(6.78)
Shareholders' funds (net worth)96.1584.8180.8473.4661.9756.7750.95
Secured loans35.6326.7022.8921.429.042.500.00
Unsecured loans1.801.501.501.512.0212.793.02
Total debt37.4328.2024.3922.9311.0615.293.02
Total liabilities13811510797.6073.8772.1653.96
Assets
Gross block13410699.4994.6687.9479.5774.09
Net block81.7958.7840.2140.2338.8535.9734.97
Capital work in progress3.137.3112.271.500.000.830.21
Investments0.000.000.000.000.000.000.00
Inventories28.9028.0929.6422.2220.2815.4411.41
Sundry debtors43.9340.1745.3941.1514.789.566.03
Cash & bank balances2.023.431.407.810.171.808.48
Loans & advances14.8013.0417.3416.1315.6522.869.95
Total current assets89.6584.7393.7787.3150.8849.6635.87
Total current liabilities37.5337.6840.4431.9916.2714.3117.10
Net working capital52.1247.0553.3355.3234.6135.3518.77
Total assets13811510797.6073.8772.1653.96
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.431.407.810.171.808.482.70
Net cash from operating activities15.3722.149.484.959.73(13.61)(34.27)
Net cash from investing activities(22.40)(21.16)(15.05)(7.49)(6.54)(5.35)32.78
Net cash from financing activities5.621.06(0.85)10.18(4.81)12.287.27
Net change in cash(1.41)2.04(6.41)7.64(1.63)(6.68)5.78
Closing cash2.023.431.407.810.171.808.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.3%-4.3%+32.2%+35.5%+19.6%+67.7%-
EBITDA growth+76.5%-18.7%-29.2%+60.2%-4.9%+146.6%-
PBT growth+164.3%-43.5%-36.7%+122.2%-10.5%+9998.0%-38.3%
Net income growth+74.3%-12.4%-34.6%+50.7%+26.6%+410.1%-
Revenue CAGR (3Y)+9.3%+19.7%+28.9%+39.5%+25.0%+14.7%-13.2%
EBITDA CAGR (3Y)+0.5%-2.7%+2.6%---+61.9%
Profitability & leverage
Net income margin+7.4%+2.9%+4.8%+9.8%+6.1%+8.2%-59.4%
Return on capital employed+8.9%+5.8%+6.3%+9.4%+5.8%+6.7%0.0%
Return on net worth+8.7%+5.0%+5.7%+8.9%+5.8%+6.5%0.0%
Debt / equity0.360.320.310.250.220.170.69
Long-term debt / equity0.180.150.120.100.090.080.33
Interest cover37.0865.9437.4819.6718.3312.71-0.39
Efficiency & per share
Fixed asset turnover1.261.421.571.261.020.930.58
Inventory turnover5.295.055.885.434.775.314.11
Debtors turnover3.583.413.524.127.009.142.75
EPS (β‚Ή)4.691.763.114.792.212.46(106.54)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)40.6435.8534.1731.0526.1924.00(18.64)

Similar companies to Bafna Pharma

Bafna Pharma has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
akums.in2004Delhi, India$70M395
CDMO focusing on spectrum of dosage forms and therapeutic segments
jubl.com1978Noida, India
Company offering a suite of R&D and manufacturing services for small molecules and generics
neclife.com1995Chandigarh, India$46.85M175
Cephalosporin APIs and generic formulations are manufactured.
Premium access

Detailed similar companies of Bafna Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Bafna Pharma

The website of Bafna Pharma (bafnapharma.com) receives about 1.3K visits a month.

  • Monthly visits
    1.3K

    ▲ 13.7% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Bafna Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bafna Pharma

BAFNAPH: Q2 EBITDA 86M RUPEES VS 42.8M (YOY); Q2 EBITDA MARGIN 18.05% VS 12.07% (YOY)
Exchange Update β€’ 11 days ago
BAFNAPH: Q2 STANDALONE NET PROFIT 68.5M RUPEES VS 31.2M (YOY)
Exchange Update β€’ 11 days ago
BAFNAPH: Q2 REVENUE 476.7M RUPEES VS 354.7M (YOY)
Exchange Update β€’ 11 days ago
Premium access

Complete news archive for Bafna Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bafna Pharma

Bafna Pharma was founded in 1981.

Bafna Pharma is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.

Bafna Pharma has 325 employees.

The primary company behind Bafna Pharma, Bafna Pharmaceuticals Limited, reported revenue of β‚Ή155 Cr for FY 2026, up 3% year on year.

Bafna Pharma was established in 1981 in Chennai, India, within the pharmaceutical sector. Manufacturing services focused on formulations are offered, with emphasis on exports to regulated and rest-of-world markets. Domestic operations were initiated in 2011 through the acquisition and launch of Raricap, targeting gynaec and paediatric segments. The company operates from its base in India to serve global and local needs.

Bafna Pharma's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.

Yes, Bafna Pharma is publicly traded on NSE under the ticker symbol BAFNAPH.

Bafna Pharma operates through Bafna Pharmaceuticals Limited.

The legal entities of Bafna Pharma currently have 9 directors, including Palamadai Krishnan Sundaresan, Ravichandran Chitra, Shanmugam Hemalatha and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available